DrugPatentWatch Database Preview
Details for Patent: 7,612,176
Which drugs does patent 7,612,176 protect, and when does it expire?
Patent 7,612,176 protects BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in two NDAs.
This patent has twenty-seven patent family members in seventeen countries.
Summary for Patent: 7,612,176
| Title: | Polymer-based sustained release device |
| Abstract: | This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. |
| Inventor(s): | Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Foxboro, MA), Rickey; Michael E. (Loveland, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA) |
| Assignee: | Alkermes, Inc. (Cambridge, MA) |
| Application Number: | 11/826,535 |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for Patent 7,612,176 |
|
Patent Claim Types: see list of patent claims | Composition; Use; |
Drugs Protected by US Patent 7,612,176
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE | ➤ Sign Up | |||
| Astrazeneca Ab | BYDUREON PEN | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-002 | Feb 28, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE | ➤ Sign Up | |||
| Astrazeneca Ab | BYDUREON BCISE | exenatide | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 209210-001 | Oct 20, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
International Family Members for US Patent 7,612,176
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005235100 | ➤ Sign Up | |||
| Brazil | PI0509946 | ➤ Sign Up | |||
| Canada | 2560874 | ➤ Sign Up | |||
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
